# Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids

> **NCT01451424** · PHASE2 · COMPLETED · sponsor: **Repros Therapeutics Inc.** · enrollment: 40 (actual)

## Conditions studied

- Uterine Fibroids

## Interventions

- **DRUG:** Proellex

## Key facts

- **NCT ID:** NCT01451424
- **Lead sponsor:** Repros Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2012-12
- **Final completion:** 2013-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01451424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01451424, "Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01451424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*